NCT07673237 · University of California, San Francisco
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
(RESPOND-ILD)
What this study is about
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.
View original scientific description
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.
Interventions
DEVICE
Spirometer
Home spirometry will be conducted weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece).
DEVICE
Oximeter
Oxygen saturation levels will be measured daily using a pulse oximeter.
DEVICE
Scale
Weight will be measured weekly using a wireless scale provided by the study.
OTHER
ePROs (electronic patient reported outcomes)
Brief electronic symptom questionnaires will be completed through a secure app which will be downloaded on participant's phone.
Primary outcome measures
Detection rate of clinically significant ILD events
Time frame: Baseline, Month 12
Measured using a composite endpoint of acute exacerbation, hospitalization, or rapid disease progression, defined as a ≥10% relative decline in FVC over 3 months
Time to detection of first ILD event
Time frame: Baseline, Month 12
Measured using a composite endpoint of acute exacerbation, hospitalization, or rapid disease progression, defined as a ≥10% relative decline in FVC over 3 months.
Adherence
Time frame: 12 months
Adherence to remote monitoring protocol, defined as the proportion of measurements completed \>=67% of weeks with full data entry)
Retention
Time frame: 12 months
Primary: Participant retention at 12 months (target \>=80%)
Data Completeness
Time frame: 12 months
Data completeness, defined as \>85% of expected remote monitoring data points successfully transmitted
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- age 18 or older
- English or Spanish speaking
- have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for \>10% of the ILD diagnoses seen at UCSF.
Exclusion criteria
- Patients who are unable provide informed consent for any reason or are acutely ill.
Where
- San Francisco, California
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), patientMpower Ltd.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Oct 9, 2026 · Source of record for eligibility and locations